Shareholders Foundation cites Oct. 31 deadline in Aardvark investor notice
The PR Newswire notice says certain Aardvark Therapeutics investors face a deadline tied to claims about IPO documents and later statements on ARD-101.
A Shareholders Foundation notice says an Oct. 31, 2026 deadline is approaching in a lawsuit tied to Aardvark Therapeutics’ IPO and later company statements.
What happened
PR Newswire published a notice on Aug. 20, 2026, from The Shareholders Foundation, Inc. saying a deadline of Oct. 31, 2026 is approaching in a lawsuit involving Aardvark Therapeutics, Inc. and its stock, which trades on Nasdaq under the ticker AARD.
The notice says it is aimed at investors who purchased more than $100,000 of Aardvark Therapeutics shares between Feb. 13, 2025 and May 14, 2026. It directs those investors to contact the Shareholders Foundation at [email protected] or +1 (858) 779-1554.
Why it matters
The notice says the lawsuit concerns claims that offering documents tied to Aardvark’s Feb. 13, 2025 initial public offering were negligently prepared and included untrue statements or omissions. It also says the complaint challenges company statements made between Feb. 13, 2025 and May 14, 2026 about the business, operations and prospects.
According to the release, the claims focus on ARD-101, with allegations that the drug candidate was less safe than investors had been led to believe and that its clinical, regulatory and commercial prospects were overstated.
Context and background
The release says a Nasdaq AARD investor filed the lawsuit on Aug. 14, 2024. It also says the offering documents were not prepared in line with applicable rules and regulations.
The notice identifies the relevant purchase window as Feb. 13, 2025 through May 14, 2026, and says the lawsuit-related deadline is Oct. 31, 2026. The release does not say in the notice whether a court has ruled on the claims.
What the release said
The Shareholders Foundation describes itself in the release as a professional portfolio legal monitoring and settlement claim filing service, not a law firm. It says any cases, investigations or settlements it references are not filed, initiated or reached by or related to it.
The notice repeats its view that public statements about Aardvark’s business and ARD-101 were materially false and misleading at all relevant times.
What happens next
According to the notice, the next stated date is Oct. 31, 2026. The release says investors in the covered share-purchase window should contact the Shareholders Foundation for more information.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()